Clopidogrel resistance and genetic polymorphism
10.3760/cma.j.issn.1673-4165.2011.11.008
- VernacularTitle:氯吡格雷抵抗与基因多态性
- Author:
Wenshan SUN
;
Yongkun LI
;
Gelin XU
- Publication Type:Journal Article
- Keywords:
Clopidogrel;
Drug resistance;
Platelet aggregation inhibitors;
Polymorphism,genetic;
Cytochrome P-450 enzyme system;
Receptors,purinergic P2Y12;
Stroke;
Myocardial infarction
- From:
International Journal of Cerebrovascular Diseases
2011;19(11):841-844
- CountryChina
- Language:Chinese
-
Abstract:
Clopidogrel is an antiplatelet drug widely used in clinical practice now.It has been used as the secondary prevention medication for myocardial infarction,ischemic stroke,and peripheral vascular disease.However,the anti-platelet aggregation effect of clopidogrel has significant individual differences.A large part of patients have clopidogrel resistance phenomenon.The mechanism of clopidogrel resistance is not fully understood.The genetic polymorphism is an important cause of clopidogrel resistance,including ABCB1,CYP2C19,CYP3A4,CYP3A5,P2Y12,and ITGB3.
